DYNE 101
Alternative Names: DYNE-101Latest Information Update: 05 Jan 2024
At a glance
- Originator Dyne Therapeutics
- Class Antibodies; Antisense oligonucleotides; Drug conjugates; Immunoconjugates; Immunoglobulin fragments
- Mechanism of Action Myotonin protein kinase expression inhibitors; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Myotonic dystrophy
Most Recent Events
- 03 Jan 2024 Efficacy, safety and pharmacodynamics data from a phase-I/II clinical trials in Myotonic dystrophy released by Dyne Therapeutics
- 20 Sep 2023 Dyne 101 receives Orphan Drug status for Myotonic dystrophy in USA
- 25 May 2023 Dyne 101 receives Orphan Drug status for Myotonic dystrophy in European Union